By Chris Wack
Renovaro Biosciences said Wednesday that it is buying BioSymetrics, an artificial intelligence-driven drug discovery and biomarker identification company.
Renovaro said the transaction will improve its data repository, biomarker discovery capabilities and accelerate translational research.
BioSymetrics' proprietary platform is called Elion, an AI and machine learning engine that uncovers complex biological relationships to speed up the discovery of diagnostics and therapeutics. Its Phenograph platform provides a translational engine that maps human clinical signals to prioritized therapeutic targets.
Renovaro said that through this merger, it will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.
The transaction is expected to close in March, subject to customary closing conditions and regulatory approvals.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 26, 2025 13:44 ET (18:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。